Corcept Therapeutics (CORT) Interest Expenses (2010 - 2026)

Corcept Therapeutics (CORT) has 17 years of Interest Expenses data on file, last reported at $11.5 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 35.31% year-over-year to $11.5 million; the trailing twelve-month figure through Mar 2026 stood at $11.5 million (up 35.31% YoY), and the FY2025 full-year result was $233000.0, down 89.54% from the prior year.
• Interest Expenses advanced to $11.5 million in Q1 2026, from $2000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $11.5 million in Q1 2026 to a low of $2000.0 in Q4 2025.
• A 5-year average of $6.3 million and a median of $8.1 million in 2022 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses surged 3045.83% in 2022 and plunged 99.62% in 2025, its largest moves.
• Tracing CORT's Interest Expenses over 5 years: stood at $2.3 million in 2022, then increased by 5.56% to $2.4 million in 2023, then slumped by 77.88% to $529000.0 in 2024, then sank by 99.62% to $2000.0 in 2025, then surged by 573950.0% to $11.5 million in 2026.
• Business Quant data shows CORT's Interest Expenses at $11.5 million in Q1 2026, $2000.0 in Q4 2025, and $7.7 million in Q3 2025.